GliaPharm SA, a biotech company that specializes in the research and development of novel therapies to treat and prevent neurological diseases, today announces the funding of its lead program in Alzheimer’s disease by the Alzheimer’s Drug Discovery Foundation (ADDF), a non-profit organization dedicated to accelerating drug discovery and development in Alzheimer’s disease. “We are pleased to see our efforts supported by the ADDF, a global leader in Alzheimer’s research,” says Sylvain Lengacher, GliaPharm’s co-CEO and co-founder. The ADDF will invest $4.2 million to bring GliaPharm’s lead compound GP-119 to the clinical stage. GP-119 is a novel orally active small molecule that acts on brain energy metabolism. “This comes as a strong validation for GliaPharm’s Alzheimer’s program and a solid partner for future developments,” adds Ambroise Magistretti, GliaPharm’s co-CEO and co-founder.
